Ann: AVITA Medical to Announce First Quarter 2023 Results, page-26

All I know is commercial revenue, excluding BARDA, is supposed to be US$10-11m. We'll find out the exact number in the morning (along with other updates) but I'd have varying degrees of happiness within this range. $10m would still be a respectable 6% growth on Q422 or 34% growth on Q122 which shows continued penetration into the U.S. and Japan burns markets.

Since this is Jim's first quarterly revenue guidance, my gut feeling is he would've pushed to get to at least US$10.3m. If they achieve this, it'll provide more confidence that he's a man who delivers on his word.

I don't think we should expect to see exceptional sales results until at least Q323 when soft tissue repair has been (hopefully) launched.